{"nctId":"NCT00814801","briefTitle":"An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease","startDateStruct":{"date":"2007-02"},"conditions":["Alzheimer's Disease"],"count":580,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Galantamine 16 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Galantamine 16 mg/day"]},{"label":"Galantamine 24 mg/day","type":"EXPERIMENTAL","interventionNames":["Drug: Galantamine 24 mg/day"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Galantamine 16 mg/day","otherNames":[]},{"name":"Galantamine 24 mg/day","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria\n* Having a Mini-Mental Status Examination (MMSE) score of 10 - 22 inclusive\n* Having an Alzheimer's Disease Assessment Scale - Japan cognitive subscale (ADAS-J cog) score of at least 18\n* Exhibiting an onset and progression of cognitive dysfunction during at least 6 months prior to the screening period\n\nExclusion Criteria:\n\n* Patients with neurodegenerative diseases other than Alzheimer's disease, such as Lewy bodies disease, (dementia due to tiny round structures made of proteins that develop within nerve cells in the brain), Parkinsonism, etc\n* Patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc\n* Patients with multi-infarct dementia (brought on by a series of strokes) or active cerebrovascular disease\n* Patients with clinically significant cardiovascular disease\n* Patients currently taking drugs such as a cholinesterase inhibitors, which improve cerebral circulation/metabolism","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Alzheimer's Disease Assessment Scale - Japan Cognitive Subscale (ADAS-J Cog)","description":"ADAS-J cog is the Japanese version of the cognitive function subscale of the Alzheimer's disease assessment scale (ADAS). This scale is used to detect changes in cognitive function in individuals with Alzheimer disease on the basis of three domains: memory, language and behavior. The minimum score is zero (0) and means well cognitive function. The maximum total score is 70 points, and the larger the score, the more severe the degree of impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"5.89"},{"groupId":"OG001","value":"-0.58","spread":"5.87"},{"groupId":"OG002","value":"-1.66","spread":"5.37"}]}]}]},{"type":"PRIMARY","title":"Distribution of Clinician's Interview-Based Impression of Change Plus - Japan (CIBIC Plus-J)","description":"CIBIC plus-J is the Japanese version of the Clinician's Interview-based Impression of Change plus the caregiver's input (CIBIC plus). It is a seven-point categorical assessment scale for evaluating the efficacy of antidementia drugs, ranging from \"markedly improved\" to \"markedly worse\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"60","spread":null},{"groupId":"OG002","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Disability Assessment for Dementia (DAD)","description":"Each of the 40 item of the DAD is scored as 1 point= Yes, 0 point= No, or non applicable= N/A. A total score (minimum=0; maximum=40) is the sum of points for each questions converted out 100. Items rated as Not Applicable (N/A) are not considered for the total score. The final score is a percentage that gives an appreciation of global function in activity of daily life (ADL). Higher scores represent less disability in ADL while lower scores indicate more dysfunction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"10.3"},{"groupId":"OG001","value":"-1.0","spread":"9.4"},{"groupId":"OG002","value":"-2.2","spread":"9.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD)","description":"Behave-AD is a CIBIC plus-J subscale that rates the patient's severity of psychotic symptoms. This four-point scale varies from 0 (=none) to 3 (= serious).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"3.1"},{"groupId":"OG001","value":"-0.2","spread":"4.2"},{"groupId":"OG002","value":"-0.3","spread":"3.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Mental Function Impairment Scale (MENFIS)","description":"MENFIS is a Clinician's Interview-Based Impression of Change (CIBIC) plus-Japan subscale that rates the patient's severity for mental function impairment. This seven-point scale varies from 0 (= absolutely no impairment) to 6 (=complete impairment).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"5.2"},{"groupId":"OG001","value":"1.6","spread":"5.2"},{"groupId":"OG002","value":"1.9","spread":"5.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":194},"commonTop":["Nasopharyngitis","Nausea","Vomiting","Fall","Diarrhoea"]}}}